ObjectiveTo explore the clinical effect of recombinant human tumor necrosis factor receptor type Ⅱ fusion protein combined with immunoadsorption in the treatment of active rheumatoid arthritis (RA). MethodsA total of 95 patients with active RA admitted to our hospital from July 2018 to November 2020 were selected as the research objects, and they were divided into control group (n=47) and observation group (n=48) by the envelope method. Patients in the control group were treated with recombinant human tumor necrosis factor receptor type Ⅱ fusion protein + leflunomide or methotrexate, based on which patients in the observation group were additionally treated with immunoadsorption, with a course of 3 months. The clinical manifestation of the two groups were compared. And the levels of immunoglobulin and blood biochemical indexes were compared between the two groups before and after treatment. ResultsBefore treatment, there were no statistically significant differences in McGlii pain questionaire (MPQ) score, disease activity score using 28 joint counts (DAS28), morning stiffness time and swollen joint count between the two groups (P＞0.05). After 3 months of treatment, MPQ score, DAS28 score, morning stiffness time and swollen joint count of the patients in the observation group were apparently lower (shorter,less) than those in the control group, with statistically significant differences (P＜0.05). Before treatment, the levels of immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG) were not significantly different between the two groups (P＞0.05). After 3 months of treatment, the levels of IgA, IgM and IgG significantly decreased in both groups, and the levels in the observation group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). Before the treatment, the levels of cytokines, erythrocyte sedimentation rate and C-reactive protein (CPR) were not significantly different between the two groups (P＞0.05) . After 3 months of treatment, the levels mentioned above obviously decreased in both groups, and the levels of patients in the observation group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). ConclusionTreatment with recombinant human tumor necrosis factor receptor typeⅡ fusion protein combined with immunoadsorption was effectively in relieving clinical symptoms such as morning stiffness, joint swelling, tenderness in patients with active RA, improving the immune function disorder, decreasing the levels of inflammatory reactions and promoting the rehabilitation of patients.

无